Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00110942 | Treatment for Patients With Osteoarthritis (OA) | PHASE2 | COMPLETED | 160 | — | — | Feb 1, 2005 | Nov 1, 2005 | Jun 23, 2008 | - | — |
| Arm | Type | Description |
|---|---|---|
| Minor sub-study AMG 108 | ACTIVE_COMPARATOR | N = 15 |
| Minor sub-study placebo | PLACEBO_COMPARATOR | N = 15 |
| Main sub-study AMG 108 | ACTIVE_COMPARATOR | N = 73 |
| Main sub-study placebo | PLACEBO_COMPARATOR | N = 73 |
| Name | Type | Description |
|---|---|---|
| Systemic AMG 108 | DRUG | 300 mg SC AMG 108 Q4W for 3 doses |
| Placebo | OTHER | SC placebo injection Q4W for 3 doses |
Inclusion Criteria: * Diagnosed with knee OA as determined by American College of Rheumatology (ACR) criteria * Pain defined by a level of greater than or equal to 30 mm on a 100 mm Visual Analogue Scale (VAS) * If currently taking any over the counter nutritional supplements, must be on stable dos...